Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | KMT2A | Q03164 | 3/20 | 0.57 |
| ▸ | MEN1 | O00255 | 2/20 | 0.57 |
| ▸ | ATM | Q13315 | 1/20 | 0.55 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.55 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.55 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | PBRM1 | Q86U86 | 1/20 | 0.47 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.46 |
| ▸ | KDM4C | Q9H3R0 | 2/20 | 0.46 |
| ▸ | KDM6B | O15054 | 1/20 | 0.46 |
| ▸ | KDM4A | O75164 | 1/20 | 0.46 |
| ▸ | KDM5C | P41229 | 1/20 | 0.46 |
| ▸ | KDM2A | Q9Y2K7 | 1/20 | 0.46 |
| ▸ | KDM3A | Q9Y4C1 | 1/20 | 0.46 |
| ▸ | SRD5A2 | P31213 | 1/20 | 0.45 |
| ▸ | RAB9A | P51151 | 4/20 | 0.45 |
| ▸ | VCAM1 | P19320 | 1/20 | 0.45 |
| ▸ | HPGD | P15428 | 1/20 | 0.45 |
| ▸ | HTT | P42858 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL27623752 | 0.90 | RECQL (0.47) | KMT2AMEN1ALDH1A1KDM4EKDM4C | |
| SCHEMBL10633320 | 0.90 | MEN1 (0.47) | KMT2AMEN1ATMTDP1L3MBTL1 | |
| SCHEMBL10633345 | 0.85 | SRD5A2 (0.52) | KMT2ASRD5A2HPGDHTTSMN1; SMN2 | |
| SCHEMBL18228667 | 0.83 | ALDH1A1 (0.49) | KMT2AMEN1ALDH1A1RAB9ASMN1; SMN2 | |
| SCHEMBL31219244 | 0.82 | KDM4C (0.65) | KMT2AMEN1ATMTDP1L3MBTL1 | |
| SCHEMBL10633305 | 0.82 | LTA4H (0.59) | KMT2AATMALDH1A1KDM4EKDM4C | |
| SCHEMBL20892726 | 0.82 | LMNA (0.55) | ALDH1A1SRD5A2RAB9AHTTSMN1; SMN2 | |
| SCHEMBL20892408 | 0.82 | LMNA (0.59) | KMT2AMEN1L3MBTL1SRD5A2RAB9A | |
| SCHEMBL40123 | 0.80 | KDM4C (0.61) | ALDH1A1KDM4EKDM4CKDM6BKDM4A | |
| SCHEMBL27160486 | 0.79 | SRD5A2 (0.57) | SRD5A2CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 18 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200339544-A1 | Epidermal growth factor receptor inhibitors | JOINT STOCK COMPANY "BIOCAD" (RU) | 2020-10-29 | — | — | US | disclosed |
| EP-3693365-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | Joint Stock Company "Biocad" (RU) | 2020-08-12 | — | — | EP | disclosed |
| WO-2019070167-A1 | EPIDERMAL GROWTH FACTOR RECEPTOR INHIBITORS | ЗАКРЫТОЕ АКЦИОНЕРНОЕ ОБЩЕСТВО "БИОКАД" | 2019-04-11 | — | — | WO | disclosed |
| CN-101805298-A | Novel aryl-with heteroaryl-piperazine | HIGH POINT PHARMACEUTICALS LLC | 2010-08-18 | — | — | CN | disclosed |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC (US) | 2009-10-22 | — | — | US | disclosed |
| CN-100334085-C | Quinuclidine compound and medicine containing the same as active ingredient | EISAI R & D CO LTD (JP) | 2007-08-29 | — | — | CN | disclosed |
| EP-1217001-B1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | EISAI CO LTD (JP) | 2005-12-07 | — | — | EP | disclosed |
| CN-1628109-A | Novel aryl-and heteroaryl-piperazines | NOVO NORDISK AS (DK) | 2005-06-15 | — | — | CN | disclosed |
| EP-1474401-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2004-11-10 | — | — | EP | disclosed |
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HIGH POINT PHARMACEUTICALS, LLC | 2003-12-25 | — | — | US | disclosed |
| WO-2003066604-A2 | NOVEL ARYL- AND HETEROARYLPIPERAZINES | NOVO NORDISK A/S (DK) | 2003-08-14 | — | — | WO | disclosed |
| US-6599917-B1 | A squalene-synthesizing enzyme inhibitor, a cholesterol biosynthesis inhibitor and a triglyceride biosynthesis inhibitor | EISAI CO., LTD. (JP) | 2003-07-29 | — | — | US | disclosed |
| CN-1377349-A | Quinuclidine compound and medicine containing the same as active ingredient | EISAI CO LTD (JP) | 2002-10-30 | — | — | CN | disclosed |
| EP-1217001-A1 | QUINUCLIDINE COMPOUNDS AND DRUGS CONTAINING THE SAME AS THE ACTIVE INGREDIENT | Eisai Co., Ltd. (JP) | 2002-06-26 | — | — | EP | disclosed |
| US-4736037-A | 2-halo-aryl-pyridinemethanols with analgesic or antiinflammatory activity | LACER, S.A. (ES) | 1988-04-05 | — | — | US | disclosed |
| US-4614833-A | 2-halo-pyridines | LACER, S.A. (ES) | 1986-09-30 | — | — | US | disclosed |
| EP-0032516-B1 | NEW 2-HALO-PYRIDINES, THEIR PRODUCTION AND PHARMACEUTICAL COMPOSITIONS | LACER, S.A. (ES) | 1984-05-02 | — | — | EP | disclosed |
| EP-0032516-A1 | New 2-halo-pyridines, their production and pharmaceutical compositions | LACER, S.A. (ES) | 1981-07-29 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20030236259-A1 | Novel aryl- and heteroarylpiperazines | HRH3, HRH2, HRH4 | KMT2A 301/4885MEN1 3565/4885ATM 4351/4885 |
| US-20200339544-A1 | Epidermal growth factor receptor inhibitors | EGFR, ERBB2, ERBB3 | KMT2A 4748/4885MEN1 2869/4885ATM 2305/4885 |
| US-20090264435-A1 | Novel Aryl- and Heteroarylpiperazines | HRH3, HRH2, HRH4 | KMT2A 301/4885MEN1 3565/4885ATM 4351/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.